601607 上海医药
已收盘 07-08 15:00:00
资讯
新帖
简况
上海医药（601607）披露控股股东增持计划实施完毕公告，7月1日股价上涨1.62%
证券之星 · 07-01
上海医药（601607）披露控股股东增持计划实施完毕公告，7月1日股价上涨1.62%
上海医药：控股股东上实集团增持计划实施完毕，增持H股7400万股
格隆汇 · 07-01
上海医药：控股股东上实集团增持计划实施完毕，增持H股7400万股
上海医药(601607.SH)：氨己烯酸口服溶液用散获得批准生产
智通财经 · 06-29
上海医药(601607.SH)：氨己烯酸口服溶液用散获得批准生产
每周股票复盘：上海医药（601607）完成董事会换届及年度股东会
证券之星 · 06-28
每周股票复盘：上海医药（601607）完成董事会换届及年度股东会
上海医药（601607）披露2025年年度股东会决议公告，6月25日股价下跌0.63%
证券之星 · 06-25
上海医药（601607）披露2025年年度股东会决议公告，6月25日股价下跌0.63%
上海医药(02607)将于8月24日派发末期股息每10股4.0477港元
智通财经 · 06-25
上海医药(02607)将于8月24日派发末期股息每10股4.0477港元
上海医药（601607）新增【养老】概念
证券之星 · 06-22
上海医药（601607）新增【养老】概念
股市必读：上海医药（601607）6月17日董秘有最新回复
证券之星 · 06-18
股市必读：上海医药（601607）6月17日董秘有最新回复
上海医药：控股股东已发布增持计划
证券之星 · 06-17
上海医药：控股股东已发布增持计划
上海医药(02607)：赵勇获选举为第九届董事会职工代表董事
智通财经 · 06-17
上海医药(02607)：赵勇获选举为第九届董事会职工代表董事
上海医药获控股股东增持3860万股H股
新浪港股 · 06-14
上海医药获控股股东增持3860万股H股
上海医药(02607)获控股股东增持3860万股 H 股
智通财经 · 06-12
上海医药(02607)获控股股东增持3860万股 H 股
上海医药：罗沙司他胶囊获批生产
第一财经 · 06-12
上海医药：罗沙司他胶囊获批生产
上海医药(02607)拟派发末期股息每10股3.5元
智通财经 · 06-03
上海医药(02607)拟派发末期股息每10股3.5元
上海医药(601607.SH)子公司山东信谊成为盐酸曲唑酮片上市许可持有人
智通财经 · 05-28
上海医药(601607.SH)子公司山东信谊成为盐酸曲唑酮片上市许可持有人
上海医药（601607）披露2026年中期分红安排公告，5月27日股价上涨0.31%
证券之星 · 05-27
上海医药（601607）披露2026年中期分红安排公告，5月27日股价上涨0.31%
上海医药：公司工业板块覆盖化学和生物药品、现代中药和保健品、医疗器械等范围
证券日报网 · 05-27
上海医药：公司工业板块覆盖化学和生物药品、现代中药和保健品、医疗器械等范围
上海医药：截至2026年第一季度B001项目用于治疗视神经脊髓炎（NMOSD）的III期临床试验主研究（RCP）已完成揭盲
证券日报网 · 05-27
上海医药：截至2026年第一季度B001项目用于治疗视神经脊髓炎（NMOSD）的III期临床试验主研究（RCP）已完成揭盲
上海医药：公司始终致力于优化业务结构，提升盈利水平
证券日报网 · 05-27
上海医药：公司始终致力于优化业务结构，提升盈利水平
上海医药(02607)：杨秋华、沈波、李永忠及董明获提名为执行董事
智通财经 · 05-27
上海医药(02607)：杨秋华、沈波、李永忠及董明获提名为执行董事
加载更多
公司概况
公司名称：
上海医药集团股份有限公司
所属行业：
零售业
上市日期：
1994-03-24
主营业务：
上海医药集团股份有限公司的主营业务是医药工业、医药商业。公司的主要产品是麝香保心丸、多糖铁复合物胶囊、胃复春胶囊、双歧杆菌三联活菌制剂、注射用乌司他丁。公司被评为2025《财富》世界500强第407位；《2025年全球医药品牌价值榜》第19位；全球十大最强医药品牌第10位；2025中国企业500强第98位；2025中国制造企业500强第36位；2025年中国医药研发产品线最佳工业企业优秀案例；中国ESG上市公司（2025）先锋100；MSCIESG评级AA级。
发行价格：
4.50
{"stockData":{"symbol":"601607","market":"SH","secType":"STK","nameCN":"上海医药","latestPrice":16.16,"timestamp":1783494001000,"preClose":16.16,"halted":0,"volume":8850500,"delay":0,"changeRate":0,"floatShares":2789000000,"shares":3708000000,"eps":1.5666,"marketStatus":"已收盘","change":0,"latestTime":"07-08 15:00:00","open":16.18,"high":16.34,"low":15.97,"amount":143000000,"amplitude":0.0229,"askPrice":16.17,"askSize":212,"bidPrice":16.16,"bidSize":98,"shortable":0,"etf":0,"ttmEps":1.5666,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1783560600000},"marketStatusCode":5,"adr":0,"adjPreClose":16.16,"symbolType":"stock","openAndCloseTimeList":[[1783474200000,1783481400000],[1783486800000,1783494000000]],"highLimit":17.78,"lowLimit":14.54,"ibTradeSell":false,"ibTradeBuySell":true,"totalEquity":3708361809,"isCdr":false,"pbRate":0.78,"roa":"--","peRate":10.315333,"roe":"1.85%","epsLYR":1.54,"committee":0.001056,"marketValue":59927000000,"turnoverRate":0.0032,"status":2,"hkstockBrief":{"symbol":"02607","market":"HK","secType":"STK","nameCN":"上海医药","latestPrice":11.86,"timestamp":1783498099006,"preClose":12,"halted":0,"volume":1274700,"delay":0,"premium":"-36.26"},"floatMarketCap":45074000000},"requestUrl":"/m/hq/s/601607","defaultTab":"news","newsList":[{"id":"2648541704","title":"上海医药（601607）披露控股股东增持计划实施完毕公告，7月1日股价上涨1.62%","url":"https://stock-news.laohu8.com/highlight/detail?id=2648541704","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2648541704?lang=zh_cn&edition=full","pubTime":"2026-07-01 22:45","pubTimestamp":1782917115,"startTime":"0","endTime":"0","summary":"截至2026年7月1日收盘，上海医药报收于15.65元，较前一交易日上涨1.62%，最新总市值为580.36亿元。近日，上海医药集团股份有限公司发布《关于控股股东增持计划实施完毕暨增持股份结果公告》。本次增持计划已实施完毕，增持后上实集团及其一致行动人合计持有公司股份1,500,255,837股，占公司总股本的40.456%。增持期间未减持所持股份，本次增持不构成要约收购，未导致公司控股股东及实际控制人变化。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026070100043659.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0209","02607","601607","BK0028","BK0012","BK0183","BK0188","BK0099","BK0196","BK0184","BK0187","BK0175","BK1197","BK0097","BK0020"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2648193705","title":"上海医药：控股股东上实集团增持计划实施完毕，增持H股7400万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2648193705","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2648193705?lang=zh_cn&edition=full","pubTime":"2026-07-01 17:14","pubTimestamp":1782897271,"startTime":"0","endTime":"0","summary":null,"market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/rss/live/live.xml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_gelonghui","symbols":["BK0196","BK0188","601607","BK0175","BK0012","BK0028","BK0097","BK0187","BK0183","BK0020","BK0184","BK0209","BK0099"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2647321345","title":"上海医药(601607.SH)：氨己烯酸口服溶液用散获得批准生产","url":"https://stock-news.laohu8.com/highlight/detail?id=2647321345","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2647321345?lang=zh_cn&edition=full","pubTime":"2026-06-29 15:44","pubTimestamp":1782719059,"startTime":"0","endTime":"0","summary":"智通财经APP讯， 上海医药(601607.SH)发布公告，近日，公司下属上海上药信谊药厂有限公司(以下简称“上药信谊”)收到国家药品监督管理局(以下简称“国家药监局”)颁发的关于氨己烯酸口服溶液用散(以下简称“该药品”)的《药品注册证书》(证书编号：2026S02303)，该药品获得批准生产。氨己烯酸口服溶液用散用于治疗婴儿痉挛症。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1460270.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0184","BK0183","BK0020","BK0188","BK0012","BK0209","BK0175","601607","BK0028","BK0099","BK0187","BK0097","BK0196","BK1197","02607"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2646318021","title":"每周股票复盘：上海医药（601607）完成董事会换届及年度股东会","url":"https://stock-news.laohu8.com/highlight/detail?id=2646318021","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2646318021?lang=zh_cn&edition=full","pubTime":"2026-06-28 01:51","pubTimestamp":1782582672,"startTime":"0","endTime":"0","summary":"截至2026年6月26日收盘，上海医药报收于15.29元，较上周的15.91元下跌3.9%。本周关注点来自公司公告汇总：上海医药选举杨秋华担任第九届董事会董事长，并聘任新一届高级管理人员。来自公司公告汇总：上海医药2025年年度股东会审议通过利润分配预案、中期分红安排等多项议案。上海医药集团股份有限公司于2026年6月25日召开2025年年度股东会，会议由董事会召集，董事长杨秋华主持，采用现场与网络投票相结合方式召开。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026062800000359.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0028","601607","02607","BK0196","BK0175","BK0183","BK0097","BK0184","BK0209","BK0012","BK0099","BK0188","BK1197","BK0187","BK0020"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2646096718","title":"上海医药（601607）披露2025年年度股东会决议公告，6月25日股价下跌0.63%","url":"https://stock-news.laohu8.com/highlight/detail?id=2646096718","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2646096718?lang=zh_cn&edition=full","pubTime":"2026-06-25 22:27","pubTimestamp":1782397637,"startTime":"0","endTime":"0","summary":"截至2026年6月25日收盘，上海医药报收于15.78元，较前一交易日下跌0.63%，最新总市值为585.18亿元。近日，上海医药集团股份有限公司披露《2025年年度股东会决议公告》。公告显示，公司于2026年6月25日召开2025年年度股东会，会议由董事会召集，董事长杨秋华主持，采用现场与网络投票相结合方式召开。国浩律师（上海）事务所对本次会议出具法律意见书，认为会议召集、召开及表决程序合法有效。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026062500044216.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["02607","BK0196","BK0184","BK1197","BK0175","601607","BK0097","BK0209","BK0028","BK0099","BK0020","BK0188","BK0183","BK0012","BK0187"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2646808724","title":"上海医药(02607)将于8月24日派发末期股息每10股4.0477港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2646808724","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2646808724?lang=zh_cn&edition=full","pubTime":"2026-06-25 20:49","pubTimestamp":1782391747,"startTime":"0","endTime":"0","summary":"智通财经APP讯，上海医药(02607)发布公告，将于2026年8月24日派发截至2025年12月31日止年度的末期股息每10股4.0477港元。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1458974.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1197","BK0175","BK0188","02607","BK4588","BK0183","BK0097","BK0196","601607","BK4585","BK0187","BK0209","BK0012","BK0184","BK0028","EWH","BK0020","BK0099","VIG"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2645224880","title":"上海医药（601607）新增【养老】概念","url":"https://stock-news.laohu8.com/highlight/detail?id=2645224880","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2645224880?lang=zh_cn&edition=full","pubTime":"2026-06-22 20:30","pubTimestamp":1782131421,"startTime":"0","endTime":"0","summary":"证券之星消息，根据市场公开信息整理，6月22日上海医药新增概念。上海医药主营业务：化学原料药、化学药制剂、抗生素、生化药品、生物制品中成药、医疗器械、制药设备、化学危险物品等的生产、销售及进出口业务。上海医药2026年一季报显示，一季度公司主营收入752.62亿元，同比上升6.36%；归母净利润14.18亿元，同比上升6.35%；扣非净利润12.38亿元，同比下降2.02%；负债率61.14%，投资收益-1411.53万元，财务费用3.57亿元，毛利率10.75%。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026062200035589.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0196","BK0175","BK0183","BK0097","BK0020","BK0184","BK0188","BK0099","601607","BK0209","BK1197","BK0028","BK0187","BK0012","02607"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2644724594","title":"股市必读：上海医药（601607）6月17日董秘有最新回复","url":"https://stock-news.laohu8.com/highlight/detail?id=2644724594","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2644724594?lang=zh_cn&edition=full","pubTime":"2026-06-18 04:55","pubTimestamp":1781729710,"startTime":"0","endTime":"0","summary":"截至2026年6月17日收盘，上海医药报收于16.11元，下跌0.25%，换手率0.26%，成交量7.34万手，成交额1.18亿元。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026061800004043.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0188","BK0184","BK1197","BK0209","BK0187","BK0183","BK0196","BK0020","601607","BK0175","BK0099","BK0097","BK0028","BK0012","02607"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2644712397","title":"上海医药：控股股东已发布增持计划","url":"https://stock-news.laohu8.com/highlight/detail?id=2644712397","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2644712397?lang=zh_cn&edition=full","pubTime":"2026-06-17 17:18","pubTimestamp":1781687887,"startTime":"0","endTime":"0","summary":"证券之星消息，上海医药06月17日在投资者关系平台上答复投资者关心的问题。公司始终将市值管理作为长期战略的重要组成部分，多措并举加强市场沟通，注重股东回报。后续公司将结合实际经营状况以及现金需求来确定未来的分红比例。本文数据来源于上海证券交易所e互动，仅供参考不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026061700029552.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0099","02607","BK0187","BK0188","BK0175","601607","BK0184","BK1197","BK0020","BK0012","BK0097","BK0183","BK0209","BK0028","BK0196"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2644871101","title":"上海医药(02607)：赵勇获选举为第九届董事会职工代表董事","url":"https://stock-news.laohu8.com/highlight/detail?id=2644871101","media":"智通财经","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2644871101?lang=zh_cn&edition=full","pubTime":"2026-06-17 16:42","pubTimestamp":1781685772,"startTime":"0","endTime":"0","summary":"智通财经APP讯，上海医药(02607)发布公告，赵勇先生(赵先生)获选举为本公司第九届董事会职工代表董事。赵先生的获选无须经本公司股东于股东会上批准。赵先生将与经本公司股东会选举产生的董事共同组成本公司第九届董事会，其任期将与第九届董事会任期一致。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1455518.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0012","BK0175","BK1197","BK0099","BK0184","BK0183","BK0188","BK0028","BK0187","601607","BK0209","BK0020","BK0196","02607","BK0097"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2643243081","title":"上海医药获控股股东增持3860万股H股","url":"https://stock-news.laohu8.com/highlight/detail?id=2643243081","media":"新浪港股","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2643243081?lang=zh_cn&edition=full","pubTime":"2026-06-14 12:37","pubTimestamp":1781411820,"startTime":"0","endTime":"0","summary":" 上海医药公布，2026 年 6 月 10 日，公司收到控股股东上海实业（集团）有限公司出具的告知函：2026 年 5 月 6 日至 2026 年 6 月 10 日期间，上海实业（集团）有限公司通过全资子公司上实国际累计增持公司3860万股H股。 本次权益变动后，上海上实（集团）有限公司持有公司股票 1，484，975，837 股，占公司总股本 3，708，361，809 股的 40.04%。权益变动方式为二级市场集中竞价交易方式，增持股份的资金来源为自有资金。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/hkstock/ggscyd/2026-06-14/doc-iniciymx9108513.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK0188","BK0184","BK1197","BK0209","BK0187","BK0183","BK0196","BK0020","601607","BK0175","BK0099","BK0097","BK0028","BK0012","02607"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2642726168","title":"上海医药(02607)获控股股东增持3860万股 H 股","url":"https://stock-news.laohu8.com/highlight/detail?id=2642726168","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2642726168?lang=zh_cn&edition=full","pubTime":"2026-06-12 17:44","pubTimestamp":1781257456,"startTime":"0","endTime":"0","summary":"智通财经APP讯，上海医药(02607)公布，2026 年 6 月 10 日，公司收到控股股东上海实业(集团)有限公司(以下简称“上实集团”)出具的告知函：2026 年 5 月 6 日至 2026 年 6 月 10 日期间，上海实业(集团)有限公司通过全资子公司上实国际累计增持公司3860万股 H 股。本次权益变动后，上海上实(集团)有限公司持有公司股票 1,484,975,837 股，占公司总股本 3,708,361,809 股的 40.04%。权益变动方式为二级市场集中竞价交易方式，增持股份的资金来源为自有资金。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1453769.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0184","BK0209","BK0097","BK0012","BK0175","BK0188","BK0187","02607","BK0099","BK1197","BK0020","BK0028","BK0196","601607","BK0183"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2642269417","title":"上海医药：罗沙司他胶囊获批生产","url":"https://stock-news.laohu8.com/highlight/detail?id=2642269417","media":"第一财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2642269417?lang=zh_cn&edition=full","pubTime":"2026-06-12 17:15","pubTimestamp":1781255740,"startTime":"0","endTime":"0","summary":"上海医药公告，公司下属公司上药国风的罗沙司他胶囊收到国家药监局颁发的药品注册证书，该药品获得批准生产。罗沙司他是一种新型的口服小分子低氧诱导因子脯氨酰羟化酶抑制剂，适用于慢性肾脏病（CKD）引起的贫血，包括透析及非透析患者。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202606123770004536.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202606123770004536.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK0020","BK0175","BK0183","BK0184","BK0012","601607","BK0188","BK0196","02607","BK0097","BK0187","BK0028","BK1197","BK0209","BK0099"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640165970","title":"上海医药(02607)拟派发末期股息每10股3.5元","url":"https://stock-news.laohu8.com/highlight/detail?id=2640165970","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2640165970?lang=zh_cn&edition=full","pubTime":"2026-06-03 17:21","pubTimestamp":1780478463,"startTime":"0","endTime":"0","summary":"智通财经APP讯，上海医药(02607)发布公告，该公司拟派发截至2025年12月31日止年度的末期股息每10股人民币3.5元。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1449633.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0012","BK0175","BK0188","VIG","BK0020","BK4588","BK0183","BK0099","BK0187","601607","BK0209","BK4585","02607","BK0097","BK0184","BK0028","BK0196","BK1197"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2638638206","title":"上海医药(601607.SH)子公司山东信谊成为盐酸曲唑酮片上市许可持有人","url":"https://stock-news.laohu8.com/highlight/detail?id=2638638206","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2638638206?lang=zh_cn&edition=full","pubTime":"2026-05-28 15:37","pubTimestamp":1779953868,"startTime":"0","endTime":"0","summary":"智通财经APP讯，上海医药(601607.SH)发布公告，近日，公司下属山东信谊制药有限公司(简称“山东信谊”)收到国家药品监督管理局颁发的《药品补充申请批准通知书》(通知书编号：2026B02904)，其同意将盐酸曲唑酮片上市许可持有人变更为山东信谊制药有限公司。盐酸曲唑酮片是河北龙海药业股份有限公司于2025年在中国批准上市的产品，适用于抑郁症的治疗，对伴有或不伴有焦虑的患者均有效。2026年5月，山东信谊就该药品上市许可持有人变更向国家药监局提出注册上市申请并获批准。截至公告日，公司针对该药品已投入约人民币520万元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1447087.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0187","BK1197","601607","BK0183","BK0209","02607","BK0097","BK0012","BK0196","BK0099","BK0175","BK0020","BK0184","BK0188","BK0028","IPOS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2638689943","title":"上海医药（601607）披露2026年中期分红安排公告，5月27日股价上涨0.31%","url":"https://stock-news.laohu8.com/highlight/detail?id=2638689943","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2638689943?lang=zh_cn&edition=full","pubTime":"2026-05-27 22:37","pubTimestamp":1779892632,"startTime":"0","endTime":"0","summary":"截至2026年5月27日收盘，上海医药报收于16.39元，较前一交易日上涨0.31%，最新总市值为607.8亿元。该股当日开盘16.35元，最高16.42元，最低16.09元，成交额达1.84亿元，换手率为0.41%。近日，上海医药集团股份有限公司发布《关于2026年中期分红安排的公告》。该议案尚需提交公司2025年年度股东会审议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026052700046303.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0184","BK0209","BK0097","BK0012","BK0175","BK0188","BK0187","02607","BK0099","BK1197","BK0020","BK0028","BK0196","601607","BK0183"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2638683269","title":"上海医药：公司工业板块覆盖化学和生物药品、现代中药和保健品、医疗器械等范围","url":"https://stock-news.laohu8.com/highlight/detail?id=2638683269","media":"证券日报网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2638683269?lang=zh_cn&edition=full","pubTime":"2026-05-27 20:33","pubTimestamp":1779885180,"startTime":"0","endTime":"0","summary":"证券日报网5月27日讯 ，上海医药在接受调研者提问时表示，公司工业板块覆盖化学和生物药品、现代中药和保健品、医疗器械等范围，聚焦免疫、精神神经、肿瘤、心血管、消化代谢及抗感染等疾病领域。公司在国内12个省市以及海外建有药品生产基地，常年生产约800个药品品规，30多种剂型。2025年公司实现工业销售过亿产品数量40个，其中过10亿产品数量4个。\n\n\n海量资讯、精准解读，尽在新浪财经APP","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"sina","url":"https://finance.sina.com.cn/stock/relnews/hk/2026-05-27/doc-inhzizpk0677953.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}.art_time, .art_cite{#sourceStyle#;} .art_cite{margin-left: 3px;}","selectors":".module-article, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/relnews/hk/2026-05-27/doc-inhzizpk0677953.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK0188","BK0175","BK1197","BK1574","BK0184","BK1583","BK0196","BK0020","BK0028","BK0209","09996","BK0012","02607","BK0097","601607","BK0183","159883","BK0099","BK1100","BK0187"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2638832606","title":"上海医药：截至2026年第一季度B001项目用于治疗视神经脊髓炎（NMOSD）的III期临床试验主研究（RCP）已完成揭盲","url":"https://stock-news.laohu8.com/highlight/detail?id=2638832606","media":"证券日报网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2638832606?lang=zh_cn&edition=full","pubTime":"2026-05-27 20:32","pubTimestamp":1779885120,"startTime":"0","endTime":"0","summary":"证券日报网5月27日讯，上海医药在接受调研者提问时表示，截至2026年第一季度，B001项目用于治疗视神经脊髓炎(NMOSD)的III期临床试验主研究(RCP)已完成揭盲。研究结果显示，B001较安慰剂可显著降低AQP4-IGG阳性NMOSD的复发风险；并且B001较已获批同类药物具备更好的安全性，输液相关不良反应、感染相关不良反应、免疫球蛋白降低和血液学相关不良反应的发生率均更低。\n\n\n海量资讯、精准解读，尽在新浪财经APP","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"sina","url":"https://finance.sina.com.cn/stock/relnews/hk/2026-05-27/doc-inhzizpk0677917.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}.art_time, .art_cite{#sourceStyle#;} .art_cite{margin-left: 3px;}","selectors":".module-article, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/relnews/hk/2026-05-27/doc-inhzizpk0677917.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK4134","BK1197","02607","BK0097","BK0175","BK0209","601607","BK0184","BK0028","BK0188","BK0099","BK0020","BK0183","BK0187","III","BK0012","BK0196"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2638268325","title":"上海医药：公司始终致力于优化业务结构，提升盈利水平","url":"https://stock-news.laohu8.com/highlight/detail?id=2638268325","media":"证券日报网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2638268325?lang=zh_cn&edition=full","pubTime":"2026-05-27 20:32","pubTimestamp":1779885120,"startTime":"0","endTime":"0","summary":"证券日报网5月27日讯，上海医药在接受调研者提问时表示，公司始终致力于优化业务结构，提升盈利水平，确保高质量发展。一方面对于存量业务，通过进一步提质增效，优化成本结构，保持毛利水平。另一方面，通过巩固创新业务优势和开拓第二增长曲线，打造新的增长引擎。在现金流管理方面，公司始终高度重视现金流安全，坚持审慎稳健的财务管控原则，通过应收账款管理、严控资本开支、优化营运资本周转等方式筑牢资金安全底线，保障公司持续健康运营。\n\n\n海量资讯、精准解读，尽在新浪财经APP","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"sina","url":"https://finance.sina.com.cn/stock/relnews/hk/2026-05-27/doc-inhzizpk9145408.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}.art_time, .art_cite{#sourceStyle#;} .art_cite{margin-left: 3px;}","selectors":".module-article, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/relnews/hk/2026-05-27/doc-inhzizpk9145408.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK0196","BK1197","BK0209","BK0028","BK0187","BK0183","BK0020","BK0097","601607","BK0012","BK0188","BK0184","BK0175","BK0099","02607"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2638503976","title":"上海医药(02607)：杨秋华、沈波、李永忠及董明获提名为执行董事","url":"https://stock-news.laohu8.com/highlight/detail?id=2638503976","media":"智通财经","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2638503976?lang=zh_cn&edition=full","pubTime":"2026-05-27 17:06","pubTimestamp":1779872765,"startTime":"0","endTime":"0","summary":"智通财经APP讯，上海医药(02607)发布公告，于2026年5月27日召开的董事会会议上，提名第九届董事会董事候选人名单如下：(i)杨秋华先生、沈波先生、李永忠先生及董明先生为第九届董事会的执行董事;(ii)张文学先生为第九届董事会的非执行董事;(iii)王忠先生、万钧女士、薛云奎先生及王迁先生为第九届董事会的独立非执行董事。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1446611.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0020","BK0175","BK0183","BK0184","BK0012","601607","BK0188","BK0196","02607","BK0097","BK0187","BK0028","BK1197","BK0209","BK0099"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"ret":0,"serverTime":1783528531941,"stockEarnings":[{"period":"1week","weight":0.0326},{"period":"1month","weight":0.0081},{"period":"3month","weight":-0.0544},{"period":"6month","weight":-0.0962},{"period":"1year","weight":-0.0817},{"period":"ytd","weight":-0.089}],"compareEarnings":[{"period":"1week","weight":-0.0344},{"period":"1month","weight":0.0029},{"period":"3month","weight":0.0012},{"period":"6month","weight":-0.0363},{"period":"1year","weight":0.1354},{"period":"ytd","weight":0.0005}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"上海医药集团股份有限公司","boardCode":"AI0052","boardName":"零售业","stockholders":"100447人(较上一季度增加Infinity%)","perCapita":"27767股","listingDate":"1994-03-24","address":"上海市浦东新区中国(上海)自由贸易试验区张江路92号","registeredCapital":"370836万元","survey":" 上海医药集团股份有限公司的主营业务是医药工业、医药商业。公司的主要产品是麝香保心丸、多糖铁复合物胶囊、胃复春胶囊、双歧杆菌三联活菌制剂、注射用乌司他丁。公司被评为2025《财富》世界500强第407位；《2025年全球医药品牌价值榜》第19位；全球十大最强医药品牌第10位；2025中国企业500强第98位；2025中国制造企业500强第36位；2025年中国医药研发产品线最佳工业企业优秀案例；中国ESG上市公司（2025）先锋100；MSCIESG评级AA级。","listedPrice":4.5},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.1","shortVersion":"4.44.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"上海医药(601607)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供上海医药(601607)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"上海医药,601607,上海医药股票,上海医药股票老虎,上海医药股票老虎国际,上海医药行情,上海医药股票行情,上海医药股价,上海医药股市,上海医药股票价格,上海医药股票交易,上海医药股票购买,上海医药股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"上海医药(601607)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供上海医药(601607)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}